MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
MedImmune announced the expansion of the MedImmune Assistance Program for Synagis designed to provide the antibody at no cost to qualifying patients who lack health insurance and whose family household income falls within a certain range of the Federal Poverty Level guidelines established by the U.S. Department of Health and Human Services. Synagis is a biologic medicine known as a monoclonal antibody administered monthly to high-risk infants to prevent serious lower respiratory tract infection caused by respiratory syncytial virus, a leading cause of viral respiratory infection among infants. [more...]
|
|
|
